购物车
- 全部删除
- 您的购物车当前为空
Tidutamab (XmAb-18087) 是一种具有完整 Fc 结构域的人源化及亲和优化双特异性抗体(bsAb),旨在通过SSTR2和CD3两个靶点特异性结合来延长血清半衰期,通过激活T细胞介导的细胞毒性(RTcC)机制,有效消除SSTR+肿瘤细胞。
Tidutamab (XmAb-18087) 是一种具有完整 Fc 结构域的人源化及亲和优化双特异性抗体(bsAb),旨在通过SSTR2和CD3两个靶点特异性结合来延长血清半衰期,通过激活T细胞介导的细胞毒性(RTcC)机制,有效消除SSTR+肿瘤细胞。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | 询价 | 期货 |
产品描述 | Tidutamab (XmAb-18087) is a bispecific antibody (bsAb) that is both humanized and optimized for affinity, targeting the SSTR2 and CD3 domains to bind to the somatostatin receptor 2 (SSTR2) and T cells, respectively. It features a full Fc domain to ensure an extended serum half-life. This compound engages in the targeted elimination of SSTR2-positive tumor cells via the mechanism of redirected T cell-mediated cytotoxicity (RTcC) [1]. |
CAS No. | 2148354-90-7 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 years | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.